Systemic Delivery of Targeted, siRNA-Containing Nanoparticles for the Treatment of Solid Tumors: Concept to Clinic

	Nanotech 2008 Vol. 2 Nanotechnology 2008: Life Sciences, Medicine & Bio Materials - Technical Proceedings of the 2008 NSTI Nanotechnology Conference and Trade Show, Volume 2 Chapter 4: Drug & Gene Delivery Systems
	Systemic Delivery of Targeted, siRNA-Containing Nanoparticles for the Treatment of Solid Tumors: Concept to Clinic
Authors:	J.D. Heidel, J.Y-C. Liu, R.K. Zeidan, Y. Liang, S. Rele, M.E. Davis
Affilation:	Calando Pharmaceuticals, US
Pages:	336 - 337
Keywords:	siRNA, deliery, RRM2, nanoparticle, transferrin
Abstract:	Calando Pharmaceuticals is developing siRNA-containing nanoparticle formulations, and its leading formulation that will enter the clinic in 2008 contains the human transferrin protein as a targeting ligand and siRNA targeting the M2 subunit of ribonucleotide reductase (RRM2). Critical parameters in the formulation and function of this therapeutic system will be highlighted using data from pre-clinical investigations. Anti-tumor efficacy is enhanced when the targeted version of the nanoparticles are employed, and results from numerous safety and efficacy studies will be discussed.
ISBN:	978-1-4200-8504-4
Pages:	808
Hardcopy:	$159.95

Order:	Mail/Fax Form
Special:	3 CD Set — 15% off with Free Shipping
Up